{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:54:44Z","timestamp":1761562484342,"version":"3.37.3"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ontario Ministry of Health and Long-Term CareOntario Ministry of Health and Long-Term Care (MOHLTC)"},{"name":"Ontario Strategy for Patient-Orientated Research (SPOR) Support Unit"},{"name":"Canadian Institutes of Health Research and the Province of Ontario"},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.drugpo.2019.01.025","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T10:42:22Z","timestamp":1549795342000},"page":"82-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Evaluation of the fentanyl patch-for-patch program in Ontario, Canada"],"prefix":"10.1016","volume":"66","author":[{"given":"Mina","family":"Tadrous","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Greaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komail","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad M.","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2008","series-title":"Compendium of pharmaceuticals and specialties","author":"Canadian Pharmaceutical Association","key":"10.1016\/j.drugpo.2019.01.025_bib0005"},{"issue":"1","key":"10.1016\/j.drugpo.2019.01.025_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1715163517743993","article-title":"Ontario Patch-for-Patch Fentanyl Return Program: 6-month review of patient returns and opinions","volume":"151","author":"Chaudhry","year":"2017","journal-title":"Canadian Pharmacists Journal : CPJ = Revue Des Pharmaciens Du Canada : RPC"},{"issue":"12","key":"10.1016\/j.drugpo.2019.01.025_bib0015","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1503\/cmaj.090784","article-title":"Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone","volume":"181","author":"Dhalla","year":"2009","journal-title":"CMAJ."},{"key":"10.1016\/j.drugpo.2019.01.025_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ypmed.2017.11.001","article-title":"The \u2018fentanyl epidemic\u2019in Canada\u2013some cautionary observations focusing on opioid-related mortality","volume":"107","author":"Fischer","year":"2017","journal-title":"Preventive Medicine"},{"issue":"2","key":"10.1016\/j.drugpo.2019.01.025_bib0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jpain.2011.09.006","article-title":"Time series analysis of California\u2019s prescription monitoring program: Impact on prescribing and multiple provider episodes","volume":"13","author":"Gilson","year":"2012","journal-title":"The Journal of Pain : Official Journal of the American Pain Society"},{"issue":"7","key":"10.1016\/j.drugpo.2019.01.025_bib0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/archinternmed.2011.117","article-title":"Opioid dose and drug-related mortality in patients with nonmalignant pain","volume":"171","author":"Gomes","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1016\/j.drugpo.2019.01.025_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jamainternmed.2016.6851","article-title":"Association of a blood glucose test strip quantity-limit policy with patient outcomes: A population-based study","volume":"177","author":"Gomes","year":"2017","journal-title":"JAMA Internal Medicine"},{"issue":"4","key":"10.1016\/j.drugpo.2019.01.025_bib0040","doi-asserted-by":"crossref","first-page":"E256","DOI":"10.9778\/cmajo.20140027","article-title":"Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: A time series analysis","volume":"2","author":"Gomes","year":"2014","journal-title":"CMAJ Open"},{"issue":"4","key":"10.1016\/j.drugpo.2019.01.025_bib0045","doi-asserted-by":"crossref","first-page":"E256","DOI":"10.9778\/cmajo.20140027","article-title":"Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: A time series analysis","volume":"2","author":"Gomes","year":"2014","journal-title":"CMAJ Open"},{"key":"10.1016\/j.drugpo.2019.01.025_bib0050","series-title":"The globe and mail","article-title":"Canada\u2019s black market for illicit drug fentanyl booming","author":"Howlett","year":"2016"},{"year":"2015","series-title":"Program fights fentanyl abuse","author":"Kelly","key":"10.1016\/j.drugpo.2019.01.025_bib0055"},{"issue":"1","key":"10.1016\/j.drugpo.2019.01.025_bib0060","doi-asserted-by":"crossref","DOI":"10.13162\/hro-ors.v6i1.3146","article-title":"Analyzing the safeguarding our communities act: Patch for patch return policy in Ontario","volume":"6","author":"Kim","year":"2018","journal-title":"Health Reform Observer\u2013Observatoire des R\u00e9formes de Sant\u00e9."},{"issue":"6","key":"10.1016\/j.drugpo.2019.01.025_bib0065","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/pm\/pnw351","article-title":"Impact of unrestricted access to pregabalin on the use of opioids and other cns-active medications: A cross-sectional time series analysis","volume":"18","author":"Kwok","year":"2017","journal-title":"Pain Medicine"},{"year":"2014","series-title":"Fentanyl abuse prevention \u2013 A shared responsibility","author":"Ontario Association of Chiefs of Police \u2013 Substance Abuse Committee","key":"10.1016\/j.drugpo.2019.01.025_bib0070"},{"year":"2016","series-title":"Ministry of health and long-term care. Fentanyl patch for patch return program","author":"Ontario Public Drug Programs Division","key":"10.1016\/j.drugpo.2019.01.025_bib0075"},{"issue":"7","key":"10.1016\/j.drugpo.2019.01.025_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098003","article-title":"The impact of drug reimbursement policy on rates of testosterone replacement therapy among older men","volume":"9","author":"Piszczek","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.drugpo.2019.01.025_bib0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/pds.1681","article-title":"Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine","volume":"18","author":"Pradel","year":"2009","journal-title":"Pharmacoepidemiology and Drug Safety"},{"year":"2017","series-title":"Opioid-related morbidity and mortality in Ontario","author":"Public Health Ontario","key":"10.1016\/j.drugpo.2019.01.025_bib0090"},{"issue":"3","key":"10.1016\/j.drugpo.2019.01.025_bib0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1526-4637.2012.01327.x","article-title":"Do prescription monitoring programs impact state trends in opioid abuse\/misuse?","volume":"13","author":"Reifler","year":"2012","journal-title":"Pain Medicine"},{"year":"2019","series-title":"Estimates of Population, by county. 0000","author":"Statistics C","key":"10.1016\/j.drugpo.2019.01.025_bib0100"},{"key":"10.1016\/j.drugpo.2019.01.025_bib0105","series-title":"Controlled substance management in chronic pain","first-page":"45","article-title":"Opioid pharmacology and pharmacokinetics","author":"Trescot","year":"2016"},{"key":"10.1016\/j.drugpo.2019.01.025_bib0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/02024458-201512000-00004","article-title":"The rise of overdose deaths involving fentanyl and the value of early warning","author":"Young","year":"2015","journal-title":"Canadian Journal Addiction."}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919300337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919300337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T06:27:16Z","timestamp":1606458436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395919300337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":22,"alternative-id":["S0955395919300337"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.025","relation":{},"ISSN":["0955-3959"],"issn-type":[{"type":"print","value":"0955-3959"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the fentanyl patch-for-patch program in Ontario, Canada","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}